Compare REX AI Equity Premium Income ETF (AIPI) vs ARK Genomic Revolution ETF (ARKG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
REX AI Equity Premium Income ETF vs ARK Genomic Revolution ETF — how do they compare? REX AI Equity Premium Income ETF trades at $36.26, while ARK Genomic Revolution ETF trades at $41.53. The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, REX AI Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.
| AIPI | ARKG | |
|---|---|---|
Sector | Income / Options Overlay | Sector/Thematic |
52-Week High | $44.93 | $43.57 |
52-Week Low | $32.45 | $23.09 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIPI trades at $37.10, up 1.87% with neutral technical signals. The ETF maintains a high weekly dividend distribution strategy, recently transitioning to weekly payouts. Technical analysis shows mixed signals with bullish moving averages but neutral oscillators, trading near key support at $37. Recent news highlights concerns about NAV erosion risk despite the attractive yield structure.
The outlook remains cautious due to structural limitations in the option-writing strategy that caps upside potential. While the ~34.8% yield appears attractive, sustainability depends heavily on AI market momentum. Investors face NAV erosion risk if technology sector performance falters, requiring careful monitoring of the fund's premium income strategy effectiveness.
ARKG trades at $43.57, up 1.54% today, with strong technical momentum as moving averages signal bullish sentiment. The ETF benefits from positive biotech sector trends including FDA friendliness and M&A activity. However, key oscillators show neutral readings with RSI indicators suggesting overbought conditions near the $45 resistance level.
The biotech ETF outlook remains favorable amid sector strength, though elevated RSI levels indicate potential near-term consolidation. Investment opportunity lies in continued sector momentum, while risks include market volatility and selective investor sentiment toward biotech companies as noted by JPMorgan bankers in June 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About REX AI Equity Premium Income ETF
AIPI provides exposure to leading artificial intelligence firms while seeking to generate monthly income. It uses a covered call strategy to capture premiums from the volatility of AI-related stocks.
Read more on AIPI →About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →
